美國居民不適用 XM 服務。
T
T

Teva

財經新聞

Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine

BRIEF-Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine July 18 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES FIRST PHASE 3 EVIDENCE OF EFFICACY AND SAFETY OF AN ANTI-CGRP MONOCLONAL ANTIBODY
T

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

UPDATE 2-US DOJ drops Viatris unit Mylan from industry-wide antitrust probe Adds background in paragraphs 2,5 and 6, updates share movement July 2 (Reuters) - Viatris VTRS.O u nit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry , the parent company said on Tuesday.
P
T

FTC starts probe into Teva about some products' patents, Washington Post reports

UPDATE 2-FTC starts probe into Teva about some products' patents, Washington Post reports Adds Teva comment in penultimate paragraph, background in last paragraph July 1 (Reuters) - The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical TEVA.TA over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
T

Drugmaker Servier loses EU court fight over pay-for-delay deals

UPDATE 1-Drugmaker Servier loses EU court fight over pay-for-delay deals Adds details By Foo Yun Chee BRUSSELS, June 27 (Reuters) - French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva TEVA.TA , Unichem and its subsidiary Niche, Matr
T

EU top court rejects Servier appeal against EU antitrust fine

EU top court rejects Servier appeal against EU antitrust fine BRUSSELS, June 27 (Reuters) - Europe's top court on Thursday rejected French drugmaker Servier's appeal against a finding by EU antitrust regulators a decade ago that its pay-for-delay deals with generic rivals were anti-competitive. "The Court dismisses the appeals of Lupin, Niche Generics, Unichem Laboratories, Matrix, Teva and Biogaran.
T

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明